Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Goldman Sachs Sticks to Buy Rating for Braveheart Bio at $48

Guavy AI Editorial Team
Instruments
GS
Share

Goldman Sachs has reaffirmed its 'buy' rating for Braveheart Bio's shares, maintaining a price target of $48.00 per share.

The firm's analyst, Salveen Richter, continues to express confidence in the biotech company's future prospects.

Despite being not yet profitable over the last twelve months, typical for development-stage biotechnology firms, Braveheart Bio has garnered attention from several analyst firms with positive ratings.

Stifel and Cantor Fitzgerald have initiated coverage with 'buy' ratings, while Jefferies and TD Cowen have also assigned 'buy' ratings to the stock.

More on Stocks

Stocks just now

Disney Legend Joe Rohde Brings 'Floating Mountains' to Castle Green

Stocks 1m ago

Disney's Magic of Animation Brings Beloved Characters Together at Hollywood Studios

Stocks 1m ago

Disney World Prepares for Crowds with Increased Lightning Lane Prices

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy